Effective use of fondaparinux in patient with unresponsiveness to nadroparin.
J Clin Pharm Ther
; 46(2): 539-542, 2021 Apr.
Article
em En
| MEDLINE
| ID: mdl-33277918
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. CASESUMMARY:
We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti-Xa measurements. The antithrombin levels were within the normal range. WHAT IS NEW ANDCONCLUSION:
To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Nadroparina
/
Heparina de Baixo Peso Molecular
/
Fondaparinux
/
Anticoagulantes
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
J Clin Pharm Ther
Assunto da revista:
FARMACIA
/
TERAPEUTICA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
República Tcheca